HL‧Max™ Platform

Zymeworks is developing an optimized monoclonal antibody constant region platform centered on conferring improved serum half-life to IgG1 therapeutic antibodies. This early-stage program is focused on optimizing a pH-dependent rescue mechanism through the engineering of improved binding to the neonatal Fc receptor (“FcRn”) while maintaining efficient release in the serum. This platform will enable Zymeworks to design more efficacious antibody therapeutics, resulting in lower dosage requirements and improved localization to the disease target.